BCG vaccine

It is a live attenuated strain of Mycobacterium bovis known as bacillus Calmette-Guérin (BCG) uses shared antigens to stimulate the development of cross-immunity to Mycobacterium tuberculosis. It lost its virulence in humans by being specially cultured in an artificial medium for years. which gives considerable protection against TB.

It is given routinely to all newborns, when vaccination is delayed to end of first year prior tuberculin testing is important, vaccine can be given to tuberculin negative children and to adolescent.

The dose is 0.1ml intradermal in the deltoid region, successful vaccine produces a small indurated area (2-4mm) after 3-4 weeks. The lesion progresses to a papule or shallow ulcer of approximately 10 mm diameter and heals within 12 weeks to form a small, flat scar.

Side effects
local abscess, axillary lymphadenitis, allergy, dizziness, vertigo, keloid scarring and disseminated BCG in immunocompromised patient.

No live vaccine should be given within 3 weeks except (OPV) and there be no vaccination in the same area for 3 months.

Efficacy 80%.

Polio vaccines

Poliovirus

Enterovirus (RNA), Three serotypes: 1, 2, 3, Human is the reservoir, transmission by fecal-oral or possible oral-oral, communicability 7-10 days before onset, the virus present in stool for 3-6 weeks. Entry into mouth, Replication in pharynx, GI tract, local lymphatic's, Hematologic spread to lymphatic's and central nervous system, Viral spread along nerve fibers leads to Destruction of motor neurons.

Most poliovirus infections are asymptomatic The two vaccines have eradicated polio from most of the countries in the world and reduced the worldwide incidence from an estimated 350,000 cases in 1988 to less than 2000 cases in 2008.

Salk’s Polio vaccine “Inactivated Polio Vaccine” IPV injectable

Based on polio grown in a type of monkey kidney tissue culture, which is then inactivated with formalin. Contains 3 serotypes of vaccine virus, the injected Salk vaccine confers IgG-mediated immunity in the
bloodstream, which prevents polio infection from progress to viremia and protects the motor neurons, thus
eliminating the risk of bulbar polio and post-polio syndrome. It offers no protection to the mucosal lining of the
intestine; i.e. people vaccinated with Salk's vaccine can still carry the disease and spread it to unvaccinated
individuals.
IPV has essentially no adverse effects associated with it other than possible rare hypersensitivity reactions to
trace quantities of antibiotics.

Sabin's polio vaccine “Oral live-attenuated vaccine”
Sabin's “Oral Polio Vaccine" is a live-attenuated vaccine, Contains 3 serotypes of vaccine virus It replicates very
efficiently in the gut, the primary site of infection and replication, Unable to replicate efficiently within nervous
system tissue, Shed in stool for up to 6 weeks following vaccination
The OPV proved to be superior in administration, and also provided longer lasting immunity than the Salk
c vaccine. The trivalent Oral Polio Vaccine (Sabin) on very rare occasions has been associated with paralysis
(vaccine-associated paralytic poliomyelitis, about 1 case per 750,000 vaccine recipients).
It is given in 3 doses, each of 2 drops(oral) at age of 2,4,6 months. A booster dose is given at age of (1.5-2years).
2nd booster dose is given at age of 4-6yrs.a period of fasting for 1-2hrs after vaccination is recommended.
Efficacy is 95%.

DPT vaccine
Diphtheria
Caused by Aerobic gram-positive bacillus; Clostridium diphtheriae, complication most attributable to toxin
Severity generally related to extent of local disease, most common complications are myocarditis and neuritis,
death occurs in 5%-10% for respiratory disease
Tetanus
Caused by Anaerobic gram-positive spore-forming bacteria; Clostridium tetani, Spores found in soil, animal
fece.s, tetanus Complications: Laryngospasm, Aspiration pneumonia and Death
Pertussis
Highly contagious respiratory infection caused by Bordetella pertussis, complication: Pneumonia, Seizures,
Encephalopathy
Mixture of 3 vaccines (toxoid of diphtheria, tetanus and killed highly antigenic organism of pertussis). Dose is
0.5ml IM given to all infants same as for OPV.
Efficacy diphtheria 87% , pertussis 80%.
– Minor reactions are quite frequent in 20–50% of vaccines. Local reactions include:
Inflammation, induration or a painless nodule at the site of injection. These are progressively more common after
the first injection
– Moderate reaction occur in 0.1% to 1.0% of children and include:
  1. ongoing crying (for three hours or more in the first 12 hours)
  2. a high fever (up to 40°C)
3. an unusual (screaming), high-pitched crying
– Severe problems happen very rarely (1 in 140,000 doses of DPT). Include;
  1. a serious allergic reaction,
  2. prolonged seizures,
  3. encephalopathy, or even death

**DT vaccine**
It is a mixture of toxoid of diphtheria & tetanus is given to children >6years of age, as pertussis vaccine is contraindicated after this age. Dose 0.5mlIM

**Measles vaccine**
It is a live attenuated vaccine given to all infants at age of 9-10 mos. But it can be given to children & adolescent too.
Dose 0.5ml S.C.(single dose). It is generally safe vaccine,
Children with egg allergy &asthmatic patient it should be given under hospital supervision.

**MMR vaccine**
It is a mixture of 3 vaccines (live attenuated of measles, mumps &rubella).
Measles; Caused by Paramyxovirus (RNA)
complication: Diarrhea, Otitis media, Pneumonia, Encephalitis
Mumps; caused by Paramyxovirus (RNA)
Complication: CNS involvement, Orchitis, Pancreatitis, Deafness
Rubella; Caused by Togavirus (RNA)
Complication in children; rare; arthralgia or arthritis, thrombocytopenic purpura, Encephalitis, Neuritis, Orchitis.
Major concern is **Congenital Rubella Syndrome** as Up to 85% of infants affected during first trimester when placenta and fetus infected during viremia; Infection may affect all organs, may lead to fetal death or premature delivery, Deafness, Cataracts, Heart defects, microcephaly, Mental retardation, Liver and spleen damage.
It is given to children at age of 15mo, it can also given to older children,A booster dose at age of 4-6years is currently recommended.
dose is 0.5ml subcutaneously (single dose).the vaccine is safe because MMR is a live-attenuated vaccine, non–allergy-related side effects are noted 5 to 12 days following immunization.
  1. Fever and rash are relatively common, experienced by 5% to 15% of recipients.
  2. Transient arthritis has been reported.
  3. Thrombocytopenia (rare)
  4. Encephalopathy (very rare)

**Contraindications and Precautions**
1. Severe allergic reaction to vaccine component or following prior dose
2. Pregnancy
3. Immunosuppression
4. Moderate or severe acute illness
5. Recent blood product

Efficacy: mumps 90%, rubella 95%.

**Hepatitis B vaccine**

Hepatitis B infection: Caused by Hepadnaviridae family (DNA). It is a recombinant DNA vaccine contains purified HBsAg particles of viruses (inactive viral antigen), produced through recombinant DNA technology in yeast.

Vaccine usually is given intramuscularly as a three-dose series, (0, 1, and 6). Three doses induce seroconversion in 90-95% of healthy infants, children and adults. Dose for infants and children is 0.5ml IM (not in the buttock). It is indicated in children & adults who are at risk of infection especially health care personnel and patients subjected to repeated blood transfusion.

**Side effects**

Transient erythema and induration at the site of injection, fever malaise, flu-like illness, arthritis, myelgia and arthralgia.

**Rotavirus vaccine**

In early childhood, the single most important cause of severe dehydrating diarrhea is rotavirus infection.

Rotaviruses; Reoviridae family, The Pentavalent vaccine protects against rotavirus gastroenteritis, Oral route,

Three doses; 2,4, and 6 months

**Meningococcal vaccine**

It is indicated at age > 2 years (it is live attenuated vaccine) in cases of

1- Functional or anatomic asplenia.
2- Travel to an endemic area.
3- Local outbreak.
4- HIV.
5- Contact of cases.
6- Terminal complement or properdin deficiency.

Dose 0.5ml SC (single dose), booster is given after 2-3 years especially in school age children.

Efficacy is 90%.

**Hemophilus influenza type b vaccine**

It is indicated for prevention of invasive diseases caused by H.influenza especially meningitis, septicemia, epiglottitis, arthritis & cellulitis, Important for infants and children <5 years (universal splenectomy & asplenia & HIV).

Dose 0.5ml IM or SC.

Efficacy 94-100%.
Pneumococcus vaccine

2 types
1- Polysaccharide protein conjugate for <2yrs    2-3 doses
2- Polysaccharide >2yrs    single dose

It is indicated for
1. Chronic respiratory diseases
2. Diabetes mellitus
3. Chronic heart diseases
4. Chronic renal diseases
5. Chronic liver diseases
6. Asplenia
7. Immunosuppression
8. Immunodeficiency
9. Hemoglobinopathies

Efficacy; type1 = 98%    type2 = 60-70%

Influenza vaccine

Inactivated virus trivalent (TIV) minimal age 6 mos.or 2 yrs. For live attenuated (LAIV)

Efficacy 50-90%.

Dose 0.5ml IM or SC for children >6yrs, 0.025ml for 1-6yrs.

Indicated in
1. Immunosuppression
2. Cardiac disease
3. Chronic lung diseases
4. Chronic renal diseases
5. Hemoglobinopathy
6. Long term aspirin treatment
7. Chronic metabolic diseases
8. Given in epidemic
9. Close contacts to above
10. Diabetes mellitus

Rabies vaccine

Inactivated virus vaccine, human diploid cell vaccine (HDCV) is available in 5 doses (1ml) at 0, 3, 7, 14, 30 days.

Efficacy; 98% in pre exposure.
Chicken pox vaccine
Live attenuated virus vaccine, it can be given above 1 year of age in a dose of 0.5ml IM or SC. And >12yrs, 2 doses with one month interval. It is indicated to a child with 13 yrs of age with no history of chicken pox and negative serology and for immunocompromised children and these with increased risk for varicella.
Precautions; DON’T give salicylate for 6 weeks after vaccination.
Efficacy 97%.

Hepatitis A vaccine
Inactivated virus, it is given as one dose followed by booster dose at 6-12mo.
Dose 0.5ml IM (1-5yrs) of age, 1ml (adult)
Indications
1. Travel to endemic area
2. During outbreak
3. Hemophilia
4. Hepatitis B, C and other chronic liver diseases
Efficacy; 80-90%.

Passive immunization
A- anti-toxins ; derived from hoarse serum used for prophylaxis and treatment of tetanus, diphtheria & others
B- Human Immunoglobulins, from human plasma, generally safe. Used for:
1- Prophylaxis against infections as chicken pox and measles.
2- Treatment of agammaglobulinemia e.g. IV immunoglobulin used in treatment of Gullain- Barrie syndrome, acute and a chronic I.T.P and neonatal septicemia.

Vaccination schedule in Iraq

<table>
<thead>
<tr>
<th>Vaccine</th>
<th>Age</th>
<th>At birth</th>
<th>2 months</th>
<th>4 months</th>
<th>6 months</th>
<th>9 months</th>
<th>15 months</th>
<th>18 months</th>
<th>4-6 years</th>
</tr>
</thead>
<tbody>
<tr>
<td>BCG</td>
<td>BCG</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>OPV</td>
<td>OPV</td>
<td>OPV</td>
<td>OPV</td>
<td>OPV</td>
<td></td>
<td>OPV</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>HBV</td>
<td>HBV</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pentavalent (DTP, Hib, and HBV)</td>
<td>Pentavalent</td>
<td>Pentavalent</td>
<td>Pentavalent</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Quadruple (DTP, and Hib)</td>
<td></td>
<td>Quadruple</td>
<td></td>
<td></td>
<td></td>
<td>Quadruple</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>DTP</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>DTP</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Measles</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Measles</td>
<td></td>
<td></td>
</tr>
<tr>
<td>MMR</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>MMR</td>
<td>MMR</td>
<td></td>
</tr>
<tr>
<td>Rotavirus</td>
<td></td>
<td>RV</td>
<td>RV</td>
<td>RV</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
### PERSONS AGED 4 MONTHS THROUGH 6 YEAR

<table>
<thead>
<tr>
<th>Vaccine</th>
<th>Minimum Age for Dose 1</th>
<th>Interval Between Doses</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>Dose 1 Dose 2</td>
</tr>
<tr>
<td>HBV</td>
<td>Birth</td>
<td>4 wks</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Rotavirus</td>
<td>6 wks</td>
<td>4 wks</td>
</tr>
<tr>
<td>DTP</td>
<td>6 wks</td>
<td>4 wks</td>
</tr>
<tr>
<td>Hib</td>
<td>6 wks</td>
<td>4 wks</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>OPV</td>
<td>6 wks</td>
<td>4 wks</td>
</tr>
<tr>
<td>MMR</td>
<td>12ms</td>
<td>4 wks</td>
</tr>
</tbody>
</table>

### PERSONS AGED 7 YEAR THROUGH 18 YEAR

<table>
<thead>
<tr>
<th>Vaccine</th>
<th>Minimum Age for Dose 1</th>
<th>Interval Between Doses</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>Dose 1 Dose 2</td>
</tr>
<tr>
<td>HBV</td>
<td>Birth</td>
<td>4 wks</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Td,Tdap</td>
<td>7yrs</td>
<td>4 wks</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>OPV</td>
<td>6 wks</td>
<td>4 wks</td>
</tr>
<tr>
<td>MMR</td>
<td>12ms</td>
<td>4 wks</td>
</tr>
</tbody>
</table>

©Tetanus and diphtheria toxoids (Td) and tetanus and diphtheria toxoids and acellular pertussis vaccine (Tdap).
- Doses of DTaP are counted as part of the Td/Tdap series.
- Tdap should be substituted for a single dose of Td in the catch-up series for children aged 7 through 10 years or as a booster for children aged 11 through 18 years; use Td for other doses.